Nomi Health

A new KFF analysis (https://www.kff.org/health-costs/issue-brief/how-many-adults-with-private-health-insurance-could-use-glp-1-drugs) revealed that over 40% of privately insured adults under 65 could be eligible for GLP-1 treatments.

As GLP-1 medications reshape the healthcare landscape, employers need expert guidance. We’re partnering with Crain's Grand Rapids Business, bringing together a panel of experts to discuss the impact of GLP-1s on employers.

Register now, and we’ll see you next Thursday, Sep. 19, at 1 p.m. ET: https://event.webcasts.com/starthere.jsp?ei=1684766&tp_key=848744d4aa

As The Washington Post reports, people are now starting to receive letters from UnitedHealth about the data breach. (Read more: https://www.washingtonpost.com/technology/2024/09/05/change-healthcare-letter-hack-data-breach/)

They're handing out paper umbrellas in a Cat5 hurricane.

Our Co-Founder and CTO Boe Hartman says, "UnitedHealth’s response to this monumental breach is not just inadequate; it’s a slap in the face to millions of us whose most sensitive data is now exposed. Their grand gesture: mailing letters to victims (while admitting they don’t even have all the addresses) and offering two years of complimentary credit monitoring and identity theft protection services."

Drawing on Nomi's extensive experience in healthcare innovation, Boe outlines in MedCity News what real, effective action should look like in the face of this unprecedented data breach: https://medcitynews.com/2024/07/credit-monitoring-wont-save-you-the-true-fallout-of-the-change-healthcare-hack-is-just-beginning/

Our Trends in Spend analysis reveals the rapid growth of GLP-1 medications for diabetes and weight loss:

💉 Now 9% of total drug spend, up from 4% in 2020

💉 Utilization soared 50% annually

💉 Weight loss prescriptions jumped from 10% to 24% in one year

💉 Costs held steady at $1,100 per prescription

These trends emphasize the importance for employers to tackle rising costs and consider the long-term health impacts.

Explore our full GLP1 trends analysis: https://www.nomihealth.com/press/weight-loss-drugs-weigh-heavy-on-employer-health-plans

This week, we launched a LinkedIn newsletter — Healthcare Rebuild — to share industry insights, grounded in facts and data, with employers and governments that no longer want to be passive buyers, providers who need more support, and informed patients who refuse to be left holding the bag.

In the Healthcare Rebuild newsletter, we'll introduce you to bright minds, bold ideas and proven tactics that are flipping healthcare on its head. The tipping point is here. Subscribe now: https://lnkd.in/dtG7z9xT

GLP-1 medications offer promising weight loss results, but come with complex considerations:

🚨 Long-term efficacy uncertainties
🚨 Ongoing safety monitoring needs
🚨 Persistent supply shortages
🚨 Off-label usage concerns
🚨 High costs averaging $936 per prescription

We understand employers must navigate these challenges while supporting employee health. Learn more about how to develop a GLP-1 strategy for your business: https://www.nomihealth.com/blog/creating-a-glp-1-weight-loss-strategy-a-guide-for-employers

We had a fantastic time at the Medicaid Enterprise Systems Community event in Louisville, KY, exchanging ideas about Medicaid systems — and the health policies impacted by those systems.

Here's our team at the event (L-R): Anna Volk, Makae Wright, Colleen Rooney and Alexander Bueno.

Since acquiring Artemis in 2022, Nomi Health has expanded to offer networks, pharmacy services (CerpassRx), healthcare financial services, and integrated care programs. Now, with Betsy McVay leading Artemis, we're enhancing these services with robust data capabilities.

Learn about our comprehensive approach: https://www.artemishealth.com/solutions/for-employers

Nomi Health is recognized as one of Utah Business's 2024 Fast 50 Emerging Companies!

The full feature is in Utah Business magazine’s September issue: https://www.utahbusiness.com/utah-fast-50-fastest-growing-companies/

Congratulations to our fellow honorees, and thank you to our team and partners for your support of our bold mission!

"We don't have a single-payer system in America, but we do have a single administrator, and that's a catastrophic vulnerability."

These words from Boe Hartman, co-founder and CTO of Nomi Health, highlight our healthcare system's fragility.

At Nomi Health, we've been speaking out about this issue since the hack on February 21. Boe's analysis, drawing on his background as a veteran of financial technology, reveals how this single point of failure threatens us all.

Welcome, Scott Williams, to the Nomi Health Global Sales team.

He brings 28 years of experience in the commercial healthcare industry to Nomi. With a successful tenure at UnitedHealthcare, Scott built a strong background in underwriting, operations and health plan leadership along with 18 years of leading the sales and account management team at UnitedHealthcare for Iowa and Central Illinois. His knowledge of the A*O marketplace, TPAs and network development position him for success in global sales at Nomi Health. Scott currently resides in Bettendorf, Iowa.

Nomi Health Co-Founder and CEO Mark Newman says prescription spending is increasing too much, too fast for self-funded employers.

“It’s a significant punch in the gut to a company’s finances. This cost crisis threatens the quality of their employee benefits. Most of all, it's completely avoidable. There are solutions here and now that enable employers to cut prescription spending in half while making sure employees get the treatments they need.”

Read more: https://www.nomihealth.com/press/high-cost-drugs-fuel-unsustainable-surge-in-prescription-spend-for-employers

Our Artemis by Nomi Health platform, now led by Betsy McVay, serves over 1,000 companies and influences $46 billion in annual health spend.

Discover how Betsy and our analytics team are making data-driven healthcare more accessible and impactful: https://www.artemishealth.com/

Did you know employers spent over $900 million on just the top three GLP-1 drugs in 2023? Ozempic led with $372M, followed by Wegovy at $261M and Mounjaro at $256M.

As these costs continue to climb, employers need to work closely with analytics partners and PBMs to develop comprehensive drug management strategies.

Here's our guide for employers on creating a GLP-1 strategy: https://www.nomihealth.com/blog/creating-a-glp-1-weight-loss-strategy-a-guide-for-employers

The Change Healthcare hack opens the door to the likelihood of unprecedented fraud.

Boe Hartman, Nomi Health's co-founder and CTO, outlines five immediate threats that demand attention. These scenarios aren't just theoretical - they're blueprints for impending chaos: https://medcitynews.com/2024/07/credit-monitoring-wont-save-you-the-true-fallout-of-the-change-healthcare-hack-is-just-beginning/

MedCity News

Welcome, Nicole Arkell — Nomi Health Senior Marketing Manager!

Nicole Arkell brings extensive healthcare industry experience from her time at Johnson & Johnson, where she managed and scaled global brands across North America, the EU, and APAC. Arkell's expertise includes pioneering new business models, driving global care strategies, and leading product innovation, all with a strong focus on the intersection of healthcare and technology. She has been instrumental in bringing innovative healthcare solutions to market, always prioritizing patient needs and improving health outcomes.

Arkell is deeply passionate about transforming healthcare and joining Nomi Health's mission to make care delivery simpler and more affordable. We're excited to welcome her to Nomi!

New data from Nomi Health reveals a 253% increase in spending on GLP-1 medications from 2020 to 2023. These weight loss and diabetes drugs now account for nearly 10% of total prescription costs for employers.

As healthcare costs continue to rise, it's crucial for employers to develop strategies to manage this trend. Read our full Trends in Spend analysis: https://www.nomihealth.com/press/weight-loss-drugs-weigh-heavy-on-employer-health-plans

Please join us in welcoming Craig Sobocinski as Nomi Health Vice President of Global Sales.

Craig Sobocinski Ed.D. brings 25 years of health insurance industry experience to Nomi Health. After 12 years of working for PGP, a large NY General Agency, Sobocinski has vastly expanded his expertise working for several organizations, including Oscar Insurance, Memorial Hermann Health Solutions, Connecture, HCSC (BCBS of Texas), and Angle Health. He currently resides in the Dallas, TX area.

Nomi Health is excited to welcome him to the team. Connect with Craig: [email protected].

Healthcare veteran Betsy McVay joins Nomi Health to lead Artemis by Nomi Health. As President, she'll apply her extensive experience to advance data-driven healthcare decisions, benefiting over 10 million Americans.

Discover Betsy's vision for the future: https://www.nomihealth.com/press/nomi-health-appoints-healthcare-veteran-betsy-mcvay-as-president-of-artemis

High-cost drugs are fueling an unsustainable surge in prescription spend for employers. According to a new analysis conducted by Nomi Health, prescriptions now account for 25% of total benefit spend. To better understand how prescription spend is accelerating at a rate four times faster than medical spend and what it could mean for your organization, read our new Trends in Spend report.- https://www.nomihealth.com/press/high-cost-drugs-fuel-unsustainable-surge-in-prescription-spend-for-employers

Nomi Health is proud to announce Betsy McVay as President of Artemis. With over two decades of healthcare data expertise, Betsy will lead our efforts to transform complex data into actionable insights.

Learn more about this strategic appointment: https://www.nomihealth.com/press/nomi-health-appoints-healthcare-veteran-betsy-mcvay-as-president-of-artemis

TODAY: Our free webinar on "Addressing the Opioid Crisis: Health Plan Strategies and Innovations Transforming Care" is today at 1:30 p.m. ET. Sara Ratner with Nomi and Dr. Andrey Ostrovsky with Social Innovation Ventures will share the latest on substance use disorders' impact on the Medicare Advantage community, innovative solutions, and actionable strategies for better care.

Join us:
https://www.risehealth.org/events/addressing-the-opioid-crisis-health-plan-strategies-and-innovations-transforming-care/

RISE

Are Pharmacy Benefit Manager (PBM) costs a ticking time bomb for self-funded insurers? Johnson & Johnson's alleged $10,000 payment for a $28 drug is a wake-up call.

That's why controlling pharmacy costs is key in a new 10-point checklist we developed to help employers mitigate their liability exposure for healthcare fiduciary responsibilities.

Our latest blog post dissects this issue and more. It's must-read material for optimizing your self-funded insurance strategy: https://lnkd.in/g99PvZbB

Dr. Don't forget! Our webinar on "Addressing the Opioid Crisis: Health Plan Strategies and Innovations Transforming Care" is happening next Tuesday, July 30, 2024, at 1:30 p.m. ET.

Hear from experts Sara Ratner of Nomi Health and Andrey Ostrovsky of Social Innovation Ventures as they share the latest on substance use disorders' impact on the Medicare Advantage community, innovative solutions, and actionable strategies for better care.

Register now: https://www.risehealth.org/events/addressing-the-opioid-crisis-health-plan-strategies-and-innovations-transforming-care/

📈 From 2022 to 2023, medical spend increased by 5%, while prescription spend soared by 18%.

📈 In 2022, the average cost employers paid — for all medications — was $450 per prescription.

Learn more about the impact on employers who self-fund their insurance: https://www.linkedin.com/pulse/5-strategies-employers-take-charge-prescription-spending-rtbsf/

Red alert for self-funded employers: Recent lawsuits involving Johnson & Johnson and Ford Motor Co. are canaries in the coal mine.

We have a 10-point checklist to help protect your company against the growing number of legal threats involving healthcare fiduciary duties — whether you're new to self-funding or optimizing your strategy. See that and dive into our latest article for a comprehensive analysis:

www.linkedin.com

The Health Care Administrators Association (HCAA) TPA Summit wrapped up yesterday. Nomi Health's financial services, Artemis and CerpassRx teams were there, meeting with innovative TPAs that found us while looking for ways to drive down costs for employers/members, improve the member experience and address fiduciary responsibility.

Pictured onsite in St. Louis (L to R): Alexander Bueno, Cameron Heiner, Nate Knudsen and Jason Wininger!

Artemis by Nomi Health

This article features commentary from Nomi Health Co-Founder and CTO Boe Hartman on the ripple effect of the data stolen in the Change Healthcare cyberattack: https://www.axios.com/2024/07/15/change-healthcare-cyberhack-fallout-risk-to-consumers

Please share. Thank you, Axios, for keeping this important conversation going.

Change Healthcare cyberhack fallout ripples to consumers Attorneys general around the U.S. issued stark warnings last week to consumers to be on the lookout for fraud resulting from the breach.

Join us for our webinar: "Addressing the Opioid Crisis: Health Plan Strategies and Innovations Transforming Care," featuring Sara Ratner from Nomi Health and Dr. Andrey Ostrovsky from Social Innovation Ventures.

Gain insights on substance use disorders' impact on the Medicare Advantage community, federal/state-level innovations, and actionable strategies for bridging care gaps.

Secure your spot now for Tuesday, July 30, 2024, at 1:30 p.m. ET: https://www.risehealth.org/events/addressing-the-opioid-crisis-health-plan-strategies-and-innovations-transforming-care/

RISE

The legal landscape of employee health benefits is changing rapidly for self-funded employers. Recent lawsuits against Johnson & Johnson and Ford Motor Co. signal a growing trend. With increased ERISA scrutiny and new transparency laws, liability risk is at an all-time high.

To help self-funded employers navigate healthcare complexities and mitigate liability exposure, we've developed a 10-point checklist. Download the checklist and read our full analysis. https://www.linkedin.com/posts/nomi-health_selffundedinsurance-legalriskmitigation-employerprotection-activity-7218962628725886976-GxI8?utm_source=share&utm_medium=member_desktop

Congratulations to Sara Ratner, President of Integrated Programs at Nomi Health, for being named one of the Top 50 Women Leaders of Minneapolis for 2024!

Sara's leadership and her commitment to improving patient care inspire us all at Nomi Health.

Read more about Sara's accomplishments:

The Top 50 Women Leaders of Minneapolis for 2024 – Women We Admire Women We Admire is pleased to announce The Top 50 Women Leaders of Minneapolis for 2024. Minneapolis is a vibrant city in the heart of the Midwest, with more than 15 Fortune 500 companies headquartered there, including Best Buy, Target, UnitedHealth, St. Jude, and General Mills. The city’s thrivin...